尼妥珠单抗同步放化疗对局部晚期不可切除食管癌的疗效及安全性研究

Abstract
Figure/Table
References (23)
Related Citation (15)

Download: PDF (441 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the efficacy and safety of Nitzumab combined with concurrent radiotherapy and chemotherapy in the treatment of locally advanced unresectable esophageal cancer, and to provide a reference for clinical treatment. Methods From January to December 2017, 94 cases with locally advanced unresectable esophageal cancer in the 902th Hospital of Chinese′s People′s Liberation Army were selected as the study subjects. They were divided into the observation group and the control group according to the random number table method, with 47 cases in each group. The control group was treated with concurrent radiotherapy and chemotherapy, and the observation group was treated with Nitzumab on the basis of the control group. The short-term efficacy, one-year and two-year survival rates, severity of toxic and side effects were compared between the two groups. Results The effective rate and control rate of the observation group were higher than those of the control group, and the differences were all statistically significant (all P < 0.05). The one-year and two-year survival rates of the observation group were higher than those of the control group, and the differences were statistically significant (P < 0.05). There were no significant differences in the severity of nausea and vomiting, rash, radiation pneumonia, radiation esophagitis and myelosuppression between the two groups(P > 0.05). Conclusion Nitzumab combined with concurrent radiotherapy and chemotherapy can improve the short-term efficacy and prolong the survival time of patients, and has the advantages of good tolerance and high safety, which has a application value.

Key words： Esophageal cancer Advanced stage Nitzumab Concurrent radiotherapy and chemotherapy Efficacy Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FANG Ping

Cite this article:

FANG Ping. The efficacy and safety of Nitzumab combined with concurrent radiotherapy and chemotherapy in the treatment of locally advanced unresectable esophageal cancer[J]. 中国医药导报, 2020, 17(22): 152-155.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I22/152

[1] 李路路，郭宇飞，张睿，等.尼妥珠单抗联合IMRT治疗根治性放化疗后局部复发食管癌的临床研究[J].长治医学院学报，2019，33（2）：134-137.
[2] Nayan N，Bhattacharyya M，Jagtap VK，et al. Standard dose versus high dose radiotherapy with concurrent chemotherapy in esophageal cancer：A prospective randomized study [J]. South Asian J Cancer，2018，7（1）：27-30.
[3] 刘向明，马明全.食管癌分子靶向治疗的新进展[J].国际生物医学工程杂志，2018，41（6）：549-555.
[4] Castro C，Peleteiro B，Morais S，et al. An explanatory and predictive model of the variation in esophageal cancer incidence on the basis of changes in the exposure to risk factors [J]. Eur J Cancer Prev，2018，27（3）：213-220.
[5] 师颖瑞.食管癌后程加速超分割调强适形放疗及和其联用尼妥珠单抗的研究[C].中国抗癌协会中国医师协会.第九届中国肿瘤内科大会、第四届中国肿瘤医师大会暨中国抗癌协会肿瘤临床化疗专业委员会2015年学术年会论文集.2015：641.
[6] 中国抗癌协会食管癌专业委员会编.食管癌规范化诊疗指南[M].北京：中国协和医科大学出版社，2013.
[7] 高献书.食管癌放射治疗指南[M].北京：中国医药科技出版社，2011.
[8] 方文涛.通过食管癌TNM新分期（第八版）解读2017年NCCN食管鳞癌诊疗指南[J].中华胃肠外科杂志，2017， 20（10）：1122-1126.
[9] 陈邓林，陈俊民，王琳.尼妥珠单抗在局部晚期食管癌治疗中的应用进展[J].现代肿瘤医学，2018，26（2）：318-321.
[10] 翟医蕊，惠周光，梁军，等.同步尼妥珠单抗联合放化疗治疗不可切除局部晚期食管鳞癌的疗效分析[J].中国临床医生杂志，2019，47（9）：1052-1055.
[11] Tachimori Y，Ozawa S，Numasaki H，et al. Comprehensive Registry of Esophageal Cancer in Japan，2011 [J]. Esophagus，2018，15（3）：1-26.
[12] 吴小源，邢文群，李雪，等.尼妥珠单抗联合术前同期放化疗治疗局部进展期食管鳞癌初步临床研究[J].中华放射肿瘤学杂志，2019，28（3）：185-187.
[13] Schlottmann F，Herbella FAM，Patti MG. Volume and Outcomes in Esophageal Cancer Surgery：Diagnosis and Treatment [M]. Esophageal Cancer，2018.
[14] 张家化，杨俊卿，罗映.单抗类抗肿瘤代表药物上市后安全信号的挖掘与评价[J].中国新药杂志，2019，28（13）：1654-1660.
[15] Joob B，Wiwanitkit V. Folate intake and risk of esophageal cancer [J]. Eur J Cancer Prev，2019，28（4）：382.
[16] Visser E ，Markar SR，Ruurda JP，et al. Prognostic Value of Lymph Node Yield on Overall Survival in Esophageal Cancer Patients：A Systematic Review and Meta-analysis [J]. Ann Surg，2018，269（2）：261-268.
[17] 刘新彦，李建斌，李志强，等.尼妥珠单抗联合顺铂治疗鼻咽癌的临床研究[J].中国临床药理学杂志，2018，34（13）：1504-1507.
[18] Semenkovich TR，Meyers BF. Surveillance versus esop-hagectomy in esophageal cancer patients with a clinical complete response after induction chemoradiation [J]. Ann Transl Med，2018，6（4）：81.
[19] 陈晓钟，金厅.靶向表皮生长因子受体治疗鼻咽癌的研究进展[J].浙江医学，2018，40（13）：1415-1418，1423.
[20] 龚星，田添，梁素美，等.尼妥珠单抗联合卡培他滨片对局部晚期鼻咽癌的临床疗效[J].中外医学研究，2019， 17（24）：26-27.
[21] 孙健达，胡丹，冯会亭，等.尼妥珠单抗治疗局部晚期鼻咽癌的临床观察[J].中国现代医生，2019，57（20）：89-93.
[22] 孙健达，胡丹，冯会亭，等.尼妥珠单抗治疗局部晚期鼻咽癌的近期疗效及不良反应分析[J].中国医药科学，2019， 9（8）：54-57.
[23] 郭银.尼妥珠单抗对食管鳞癌ECA-109细胞放射敏感性的影响及机制研究[D].石家庄：河北医科大学，2015.